CHANG Hui mei, entered into sale and purchase agreement to acquire 40% interest in Bau Shan Life Science Technology Co., Ltd from Sino-Life Group Limited (SEHK:8296) for approximately CNY 14 million on December 14, 2018. The consideration will be paid in cash, of which 10% is payable upon the signing of the sale and purchase agreement, 40% is payable upon the endorsement of shares, and the remaining 50% is payable within one month after the completion. Under the terms, Sino-Life Group is selling 2.8 million ordinary shares. Post completion, Sino-Life Group Limited's stake in Bau Shan Life Science Technology will reduce to 60%. Bau Shan Life Science Technology reported revenues of CNY 2.3 million and loss after tax of CNY 10.7 million for the year ended December 31, 2017. Transaction is expected to be completed in around May 2019. Sino-Life Group Limited intends to apply the net proceeds from the disposal as funding for the it’s biological technology industry development. CHANG Hui mei, completed the acquisition of 40% interest in Bau Shan Life Science Technology Co., Ltd from Sino-Life Group Limited (SEHK:8296) in April, 2019.